The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | Promising results for venetoclax combination therapies in elderly AML
In this exciting interview, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, provides optimistic preliminary results from clinical trials (NCT02287233 and NCT02203773) utilizing venetoclax in elderly acute myeloid leukemia (AML) patients. Thus, Dr Konopleva is hopeful for the approval of venetoclax in combination therapies for AML. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
